

DAFTAR PUSTAKA

- Allredge, B.K., Corelli, R.L., Ernst, M.E., Guglielmo, B.J., Jacobson, P.A., Kradjan, W.A., dkk., 2013. Koda-kimble & Young's: Applied Therapeutics The Clinical Use of Drugs Tenth Edition. *Lippincott Williams & Wilkins*, 10: 1929-1946.
- Adnet, P., Lestavel, P., dan Krivosic-Horber, R., 2000. Neuroleptic malignant syndrome. *British Journal of Anaesthesia*, **85**: 129–135.
- Amato, D., Canneva, F., Cumming, P., Maschauer, S., Groos, D., Dahlmanns, J.K., dkk., 2020. A dopaminergic mechanism of antipsychotic drug efficacy, failure, and failure reversal: the role of the dopamine transporter. *Molecular Psychiatry*, **25**: 2101–2118.
- Ananth, J., Aduri, K., Parameswaran, S., dan Gunatilake, S., 2004. Neuroleptic malignant syndrome: risk factors, pathophysiology, and treatment. *Acta Neuropsychiatrica*, **16**: 219–228.
- Barrera, A., Curwell-Parry, O., dan Raphael, M.-C., 2019. Hebeephrenia is dead, long live hebephrenia, or why Hecker and Chaslin were on to something. *BJPsych Advances*, **25**: 373–376.
- Belvederi Murri, M., Guaglianone, A., Bugliani, M., Calcagno, P., Respino, M., Serafini, G., dkk., 2015. Second-Generation Antipsychotics and Neuroleptic Malignant Syndrome: Systematic Review and Case Report Analysis. *Drugs in R&D*, **15**: 45–62.
- Berardi, D., Amore, M., Keck, P.E., Troia, M., dan Dell'Atti, M., 1998. Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: a case–control study. *Biological Psychiatry*, **44**: 748–754.
- Berman, B.D., 2011. Neuroleptic Malignant Syndrome: A Review for Neurohospitalists. *The Neurohospitalist*, **1**: 41–47.
- Brunton, L.L., Lazo, J.S., dan Parker, K.L., 2006. Goodman & Gilman's: The Pharmacological Basis of Therapeutics Eleventh Edition. *The McGraw-Hill Companies*, 11: 461-492.
- Carton L, Cottencin O, Lapeyre-Mestre M, dkk., 2015. Off-label prescribing of antipsychotics in adults, children and elderly individuals: a systematic review of recent prescription trends. *Current Pharmaceutical Design*, **21**: 3280–97.
- Chen, Y., Guo, J.J., Steinbuch, M., Buckley, P.F., dan Patel, N.C., 2009. Risk of *Neuroleptic malignant syndrome* in Patients with Bipolar Disorder: A Retrospective, Population-Based Case-Control Study. *The International Journal of Psychiatry in Medicine*, **39**: 439–450.
- Edwards, I.R. dan Aronson, J.K., 2000. Adverse drug reactions: definitions, diagnosis, and management. *The Lancet*, **356**: 1255–1259.
- Foster, A. dan King, J., 2020. Antipsychotic Polypharmacy. *FOCUS*, **18**: 375–385.
- Freudenreich, O., 2020. *Psychotic Disorders: A Practical Guide*, Current Clinical Psychiatry. Springer International Publishing, Cham.
- Fukuta, Y. dan Muder, R.R., 2013. Infections in Psychiatric Facilities, with an Emphasis

- D'Alli, R.E., 2009. Child And Adolescent Psychopharmacology. *Developmental-Behavioral Pediatrics (Fourth Edition)*, , Child And Adolescent Psychopharmacology **4**: 885–909.
- Gallego JA, Bonetti J, Zhang J, dkk., 2012. Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. *Schizophrenia Research*, **138**: 18–28.
- Gillies, D., Beck, A., McCloud, A., dan Rathbone, J., 2005. Benzodiazepines for psychosis-induced aggression or agitation, dalam: The Cochrane Collaboration (Editor), *Cochrane Database of Systematic Reviews*. John Wiley & Sons, Ltd, Chichester, UK, hal. CD003079.pub2.
- Gogos, A., Sbisà, A.M., Sun, J., Gibbons, A., Udawela, M., dan Dean, B., 2015. A Role for Estrogen in Schizophrenia: Clinical and Preclinical Findings. *International Journal of Endocrinology*, **2015**: 1–16.
- Guinart, D., Taipale, H., Rubio, J.M., Tanskanen, A., Correll, C.U., Tiihonen, J., dkk., 2021. Risk Factors, Incidence, and Outcomes of Neuroleptic Malignant Syndrome on Long-Acting Injectable vs Oral Antipsychotics in a Nationwide Schizophrenia Cohort. *Schizophrenia Bulletin*, **47**: 1621–1630.
- Guo, J.J., Wu, J., Kelton, C.M.L., Jing, Y., Fan, H., Keck, P.E., dkk., 2012. Exposure to Potentially Dangerous Drug-Drug Interactions Involving Antipsychotics. *Psychiatric Services*, **63**: 1080–1088.
- Gurrera, R.J., 2017. A systematic review of sex and age factors in neuroleptic malignant syndrome diagnosis frequency. *Acta Psychiatrica Scandinavica*, **135**: 398–408.
- Hirofuji, S., Miyasaka, K., Maezawa, M., Wakabayashi, W., Oura, K., Nakao, S., dkk., 2023. Evaluation of neuroleptic malignant syndrome induced by antipsychotic drugs using spontaneous reporting system. *Heliyon*, **9**: e21891.
- Kaar, S.J., Natesan, S., McCutcheon, R., dan Howes, O.D., 2020. Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology. *Neuropharmacology*, **172**: 107704.
- Kamei, H., 2022. Polypharmacy Management of Antipsychotics in Patients with Schizophrenia. *Medicina*, **58**: 1584.
- Kementerian Kesehatan Republik Indonesia, 2015. *Pedoman Nasional Pelayanan Kedokteran Jiwa*, Jakarta, Kementerian Kesehatan Republik Indonesia
- Kementerian Kesehatan Republik Indonesia, 2018. *InfoDATIN Pusat Data dan Informasi Kementerian Kesehatan RI: Situasi Kesehatan Jiwa di Indonesia*, Jakarta, Kementerian Kesehatan Republik Indonesia
- Kim, H.-Y., Lee, H.-W., Jung, S.-H., Kang, M.-H., Bae, J.-N., Lee, J.-S., dkk., 2014. Prescription Patterns for Patients with Schizophrenia in Korea: A Focus on Antipsychotic Polypharmacy. *Clinical Psychopharmacology and Neuroscience*, **12**: 128–136.
- Kimura, G., Kadoyama, K., Brown, J.B., Nakamura, T., Miki, I., Nisiguchi, K., dkk., 2015. Antipsychotics-Associated Serious Adverse Events in Children:

- An Analysis of the FAERS Database. *International Journal of Medical Sciences*, **12**: 135–140.
- Lähteen vu o, M. dan Ti i honen, J., 2021. Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations. *Drugs*, **81**: 1273–1284.
- Lally, J. dan MacCabe, J.H., 2015. Antipsychotic medication in schizophrenia: a review. *British Medical Bulletin*, **114**: 169–179.
- Langan, J., Martin, D., Shajahan, P., dan Smith, D.J., 2012. Antipsychotic dose escalation as a trigger for Neuroleptic Malignant Syndrome (NMS): literature review and case series report. *BMC Psychiatry*, **12**: 214.
- Lao, K.S.J., Zhao, J., Blais, J.E., Lam, L., Wong, I.C.K., Besag, F.M.C., dkk., 2020. Antipsychotics and Risk of Neuroleptic Malignant Syndrome: A Population-Based Cohort and Case-Crossover Study. *CNS Drugs*, **34**: 1165–1175.
- Mann, S.C., Caroff, S.N., Fricchione, G., Campbell, C., 2000. Central dopamine hypoactivity and the pathogenesis of *Neuroleptic malignant syndrome*. *Psychiatr. Ann.* 30 (5), 363–374
- Miller, J., 2021. Managing acute agitation and aggression in the world of drug shortages. *Mental Health Clinician*, **11**: 334–346.
- Misawa, F., Okumura, Y., Takeuchi, Y., Fujii, Y., dan Takeuchi, H., 2021. Neuroleptic malignant syndrome associated with long-acting injectable versus oral second-generation antipsychotics: Analyses based on a spontaneous reporting system database in Japan. *Schizophrenia Research*, **231**: 42–46.
- Morris, E., Green, D., dan Graudins, A., 2009. Neuroleptic malignant syndrome developing after acute overdose with olanzapine and chlorpromazine. *Journal of Medical Toxicology*, **5**: 27–31.
- Muench, J. dan Hamer, A.M., 2010. Adverse Effects of Antipsychotic Medications. *Am Fam Physician*, **81**: 617–622.
- Nielsen, R.E., Jensen, S.O.W., dan Nielsen, J., 2012. Neuroleptic Malignant Syndrome—An 11-Year Longitudinal Case-Control Study. *The Canadian Journal of Psychiatry*, **57**: 512–518.
- Neuhut, R., Lindenmayer, J.-P., dan Silva, R., 2009. Neuroleptic Malignant Syndrome in Children and Adolescents on Atypical Antipsychotic Medication: A Review. *Journ*
- Nishanth, K.N., Chadda, R.K., Sood, M., Biswas, A., dan Lakshmy, R., 2017. Physical comorbidity in schizophrenia & its correlates. *INDIAN J MED RES*,
- Oneib, B. dan Zaimi, O., 2021. Neuroleptic malignant syndrome: clinical expression, complication, course, and atypical clinical picture. *Middle East Current Psychiatry*, **28**: 1.
- Oruch, R., Pryme, I., Engelsens, B., dan Lund, A., 2017. Neuroleptic malignant syndrome: an easily overlooked neurologic emergency. *Neuropsychiatric Disease and Treatment*, **Volume 13**: 161–175.
- Ouyang Z, Chu L., 2013. A case of recurrent *Neuroleptic malignant syndrome*. *Shanghai Archives of Psychiatry*, 25: 256–8.

- Quock, R.M., 2022. Discovering Psychology Series: Drugs and Behavior 2nd edition. *Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License*.
- Pankiewicz-Dulacz, M., Stenager, Egon, Chen, M., dan Stenager, Elsebeth, 2018. Incidence Rates and Risk of Hospital Registered Infections among Schizophrenia Patients before and after Onset of Illness: A Population-Based Nationwide Register Study. *Journal of Clinical Medicine*, **7**: 485.
- Patel, K.R., Cherian, J., Gohil, K., dan Atkinson, D., 2004. Schizophrenia: Overview and Treatment Options. *P&T*, **39**:
- Paton, C., Barnes, T.R.E., Cavanagh, M.-R., Taylor, D., dan Lelliott, P., 2008. High-dose and combination antipsychotic prescribing in acute adult wards in the UK: The challenges posed by p.r.n. prescribing. *British Journal of Psychiatry*, **192**: 435–439.
- Pierre, J.M., 2020. For emergency agitation, evidence suggests newer alternatives may be a better choice. *Current Psychiatry*, **19**: 19–28.
- Pileggi, D.J. dan Cook, A.M., 2016. Neuroleptic Malignant Syndrome Review. *Annals of Pharmacotherapy*, 1–9.
- Raja, M., 2009. Pharmacotherapy Update: Risperidone in the Treatment of Schizophrenia. *Clinical Medicine. Therapeutics*, **1**: CMT.S1123.
- Sahin, A., Cicek, M., Gonenc Cekic, O., Gunaydin, M., Aykut, D.S., Tatli, O., dkk., 2017. A retrospective analysis of cases with neuroleptic malignant syndrome and an evaluation of risk factors for mortality. *Turkish Journal of Emergency Medicine*, **17**: 141–145.
- Sarkar, S. dan Gupta, N., 2017. Drug information update. Atypical antipsychotics and neuroleptic malignant syndrome: Nuances and pragmatics of the association. *BJPsych Bulletin*, **41**: 211–216.
- Severance, E.G., Prandovszky, E., Castiglione, J., dan Yolken, R.H., 2015. Gastroenterology Issues in Schizophrenia: Why the Gut Matters. *Current Psychiatry Reports*, **17**: 27.
- Shaikh, N., Al-Sulaiti, G., Nasser, A., dan Rahman, M., 2011. Neuroleptic malignant syndrome and closed head injury: A case report and review. *Asian Journal of Neurosurgery*, **6**: 101–105.
- Stevens, D.L., 2008. Association Between Selective Serotonin-Reuptake Inhibitors, Second-Generation Antipsychotics, and Neuroleptic Malignant Syndrome. *Annals of Pharmacotherapy*, **42**: 1290–1297.
- Strawn, J.R., Keck, P.E., dan Caroff, S.N., 2007. Neuroleptic Malignant Syndrome. *Am J Psychiatry*, .
- Su, Y.-P., Chang, C.-K., Hayes, R.D., Harrison, S., Lee, W., Broadbent, M., dkk., 2014. Retrospective chart review on exposure to psychotropic medications associated with neuroleptic malignant syndrome. *Acta Psychiatrica Scandinavica*, **130**: 52–60.
- Touzani, S., Hamdouni, M., Houari, N., Khbiza, Y.Y., Elbouazzaoui, A., Boukatta, B., dkk., 2021. Neuroleptic malignant syndrome cases in a Moroccan intensive care unit: a retrospective analysis and literature review. *Journal of Neurocritical Care*, **14**: 88–97.

- Tandon, R., 2011. Antipsychotics in the Treatment of Schizophrenia: An Overview. *The Journal of Clinical Psychiatry*, **72**: .
- Trollor, J.N. dan Sachdev, P.S., 1999. Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases. *Australian and New Zealand Journal of Psychiatry*, **33**: 650–659.
- Tsai, M.-C. dan Huang, T.-L., 2010. Severe Neuroleptic Malignant Syndrome: Successful Treatment with High-dose Lorazepam and Diazepam: A Case Report **33**: .
- Tse, L., Barr, A., Scarapicchia, V., dan Vila-Rodriguez, F., 2015. Neuroleptic Malignant Syndrome: A Review from a Clinically Oriented Perspective. *Current Neuropharmacology*, **13**: 395–406.
- Tseng, P.-T., Chen, Y.-W., Chung, W., Tu, K.-Y., Wang, H.-Y., Wu, C.-K., dkk., 2016. Significant Effect of Valproate Augmentation Therapy in Patients With Schizophrenia: A Meta-analysis Study. *Medicine*, **95**: e2475.
- Tural, Ü. dan Önder, E., 2010. Clinical and pharmacologic risk factors for neuroleptic malignant syndrome and their association with death. *Psychiatry and Clinical Neurosciences*, **64**: 79–87.
- Velamoor, R., 2017. Neuroleptic malignant syndrome: A neuro-psychiatric emergency: Recognition, prevention, and management. *Asian Journal of Psychiatry*, **29**: 106–109.
- Verma, R., Junewar, V., dan Rathaur, B.P.S., 2014. An atypical case of neuroleptic malignant syndrome precipitated by valproate. *Case Reports*, **2014**: bcr2013202578–bcr2013202578.
- Viejo, L.F., Morales, V., Puñal, P., Pérez, J.L., dan Sancho, R.A., 2003. Risk factors in *Neuroleptic malignant syndrome*. A case-control study: **Case-control: risk factors in NMS**. *Acta Psychiatrica Scandinavica*, **107**: 45–49.
- Wadoo, O., Ouanes, S., dan Firdosi, M., 2021. Neuroleptic malignant syndrome: a guide for psychiatrists. *BJPsych Advances*, **27**: 373–382.